Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database

References

• Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia (Nathan). 2019;11:3. doi:10.1186/s41479-019-0062-0.
   PubMedGoogle Scholar
• Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321. doi:10.3389/fped.2018.00321.
   PubMed Web of Science ®Google Scholar
• Stephens DS. Neisseria meningitidis. Infect Control. 1985;6:37–11. doi:10.1017/S0195941700062482.
   PubMedGoogle Scholar
• Whittaker R, Dias JG, Ramliden M, Kodmon C, Economopoulou A, Beer N, Pastore Celentano L, Kanitz E, Richter L, Mattheus W, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35:2034–41. doi:10.1016/j.vaccine.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:17. doi:10.1186/1478-7954-11-17.
   PubMed Web of Science ®Google Scholar
• Parent du Chatelet I, Deghmane AE, Antona D, Hong E, Fonteneau L, Taha MK, Lévy-Bruhl, D . Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015. J Infect. 2017;74:564–74. doi:10.1016/j.jinf.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Taha MK, Weil-Olivier C, Bouée S, Emery C, Nachbaur G, Pribil C, Loncle-Provot, V. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021;17:1858–66. doi:10.1080/21645515.2020.1849518.
   PubMed Web of Science ®Google Scholar
• Taha MK, Gaudelus J, Deghmane AE, Caron F. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother. 2020;1–6. doi:10.1080/21645515.2020.1704580.
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63. doi:10.1016/j.vaccine.2009.04.063.
   PubMed Web of Science ®Google Scholar
• Strifler L, Morris SK, Dang V, Tu HA, Minhas RS, Jamieson FB, Deeks SL, Crowcroft NS, Sander B. The health burden of invasive meningococcal disease: a systematic review. J Pediatric Infect Dis Soc. 2016;5:417–30. doi:10.1093/jpids/piv065.
   PubMed Web of Science ®Google Scholar
• Olbrich KJ, Muller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421–38. doi:10.1007/s40121-018-0213-2.
   PubMed Web of Science ®Google Scholar
• Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, Joosten KFM. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. 2009;94:381–86. doi:10.1136/adc.2007.131862.
   PubMed Web of Science ®Google Scholar
• Société de Pathologie Infectieuse de Langue Française. 17e Conférence de Consensus en Thérapeutique Anti-Infectieuse. Prise en charge des méningites bactériennes aiguës communautaires (à l’exclusion du nouveau-né). 2008.
   Google Scholar
• Pearce J, Peters M, May N, Marshall H, Hein C, Grantham H. Care of the patient with invasive meningococcal disease by prehospital emergency medical service clinicians: a scoping review. BMJ Open. 2020;10:e033447. doi:10.1136/bmjopen-2019-033447.
   PubMed Web of Science ®Google Scholar
• Huang L, Heuer OD, Janssen S, Hackl D, Schmedt N. Clinical and economic burden of invasive meningococcal disease: evidence from a large German claims database. PLoS One. 2020;15:e0228020. doi:10.1371/journal.pone.0228020.
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health. 2006;9:236–43. doi:10.1111/j.1524-4733.2006.00113.x.
   PubMed Web of Science ®Google Scholar
• Davis KL, Bell TJ, Miller JM, Misurski DA, Bapat B. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US. Appl Health Econ Health Policy. 2011;9:197–207. doi:10.2165/11587330-000000000-00000.
   PubMedGoogle Scholar
• Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vaccin. 2011;7:96–101. doi:10.4161/hv.7.1.13692.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Christensen H, Agnew E, Trotter C, Robays J, Dubois C, Van de Sande, S, Thiry, N . A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study. Health Technology Assessment KCE Report 231. Belguim (Brussels): KCE Belgian Health Care Knowledge Centre; . 14 2014 October Accessed 03 November 2021 https://kce.fgov.be/sites/default/files/atoms/files/KCE_231_Meningococcal_disease_Report.pdf
   Google Scholar
• Karve S, Misurski D, Miller J, Davis KL. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med. 2011;2:e215–26. doi:10.1016/j.ehrm.2011.08.001.
   Google Scholar
• Gil-Prieto R, García-García L, Alvaro-Meca A, González-Escalada A, Viguera Ester P, Gil de Miguel A. The burden of hospitalizations for meningococcal infection in Spain (1997-2008). Vaccine. 2011;29:5765–70. doi:10.1016/j.vaccine.2011.05.089.
   PubMed Web of Science ®Google Scholar
• Montero JM, Prieto RG, Alejandre CG, Meca LA, Portugal P, de Miguel AG. Hospital admissions for meningococcal infection in Spain (1997-2005). J Infect. 2009;58:15–20. doi:10.1016/j.jinf.2008.10.009.
   PubMed Web of Science ®Google Scholar
• Weil-Olivier C, Taha MK, Emery C, Bouée S, Beck E, Aris E, Loncle-Provot V, Nachbaur G, Pribil C. Healthcare resource consumption and cost of invasive meningococcal disease in France: a study of the national health insurance database. Infect Dis Ther 2021;10:1607–23. doi:10.1007/s40121-021-00468-w.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397–403. doi:10.1016/S0140-6736(06)67932-4.
   PubMed Web of Science ®Google Scholar
• Krone M, Lâm TT, Claus H, Vogel U. Recurrent invasive meningococcal infections - quantifying the risk, Germany, 2002 to 2018. Euro Surveill. 2020;25 1900565 . doi:10.2807/1560-7917.ES.2020.25.25.1900565.
   Google Scholar
• Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83. doi:10.1016/S1474-4422(12)70180-1.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R . The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32:e20–5. doi:10.1097/INF.0b013e3182706b89.
   PubMed Web of Science ®Google Scholar
• Quantin C. Etude des algorithmes de définition de pathologies dans le système national d’information inter-régimes de l’assurance maladie (SNIIRAM). France,Paris: Caisse nationale d’Assurance maladie des travailleurs salariés; 2015.
   Google Scholar
• Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91–104. doi:10.1016/j.jval.2020.09.004.
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51. doi:10.1111/1469-0691.12461.
   PubMed Web of Science ®Google Scholar
• Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, et al. Influenza. Nat Rev Dis Primers. 2018;4:3. doi:10.1038/s41572-018-0002-y.
   PubMed Web of Science ®Google Scholar
• Haj-Hassan TA, Thompson MJ, Mayon-White RT, Ninis N, Harnden A, Smith LF, Perera R, Mant DC. Which early ‘red flag’ symptoms identify children with meningococcal disease in primary care? Br J Gen Pract. 2011;61(584):e97–104. doi:10.3399/bjgp11X561131.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Campbell H, Gray SJ, Beebeejaun K, Ribeiro S, Borrow R, Ramsay ME, Ladhani SN. Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015. Vaccine. 2018;36:3876–81. doi:10.1016/j.vaccine.2018.02.038.
   PubMed Web of Science ®Google Scholar
• Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015-2018. Clin Infect Dis. 2020;70:2036–44. doi:10.1093/cid/ciz578.
   PubMed Web of Science ®Google Scholar
• Adriani KS, van de Beek D, Brouwer MC, Spanjaard L, de Gans J. Community-acquired recurrent bacterial meningitis in adults. Clin Infect Dis. 2007;45:e46–51. doi:10.1086/520682.
   PubMed Web of Science ®Google Scholar
• Drummond DS, de Jong AL, Giannoni C, Sulek M, Friedman EM. Recurrent meningitis in the pediatric patient–the otolaryngologist’s role. Int J Pediatr Otorhinolaryngol. 1999;48:199–208. doi:10.1016/S0165-5876(99)00022-1.
   PubMed Web of Science ®Google Scholar
• Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr., Swartz MN. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med. 1993;328:21–28. doi:10.1056/NEJM199301073280104.
   PubMed Web of Science ®Google Scholar
• igurdardóttir B, Björnsson OM, Jónsdóttir KE, Erlendsdóttir H, Gudmundsson S. Acute bacterial meningitis in adults. A 20-year overview. Arch Intern Med. 1997;157:425–30. doi:10.1001/archinte.1997.00440250077009.
   PubMedGoogle Scholar
• Rosain J, Hong E, Fieschi C, Martins PV, El Sissy C, Deghmane AE, Ouachée M, Thomas C, Launay D, de Pontual L. Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies. J Infect Dis. 2017;215:1331–38. doi:10.1093/infdis/jix143.
   PubMed Web of Science ®Google Scholar
• Roed C, Omland LH, Engsig FN, Skinhoj P, Obel N. Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study. PLoS One. 2010;5:e9662. doi:10.1371/journal.pone.0009662.
   PubMed Web of Science ®Google Scholar
• Hellenbrand W. (Invasive Meningococcal Disease 2012 - 2015). Invasive Meningokokken-Erkrankungen 2012 – 2015. Epidemiologisches Bulletin. 2016;471–84.
   Google Scholar
• Public Health England. Meningococcal disease: laboratory confirmed cases in England in 2019 to 2020. United Kingdom (London): Public Health England.12 January2021. Accessed 03 November 2021. https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-in-2019-to-2020
   Google Scholar
• Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37:2768–82. doi:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Vyse A, Anonychuk A, Jakel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11:597–604. doi:10.1586/eri.13.42.
   PubMed Web of Science ®Google Scholar
• Gaudelus J, Cohen R, Leboucher B, Stahl JP, Denis F, Pujol P, Longfier L, Martinot A. Meningococcal C vaccine coverage in France in infants, children, and adolescents. Med Mal Infect. 2019;49:180–86. doi:10.1016/j.medmal.2019.01.014.
   PubMed Web of Science ®Google Scholar
• Garrido-Estepa M, León-Gómez I, Herruzo R, Cano R. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine. 2014;32:2604–09. doi:10.1016/j.vaccine.2014.03.010.
   PubMed Web of Science ®Google Scholar
• Mooney JD, Christie P, Robertson C, Clarke SC. The impact of meningococcal serogroup C conjugate vaccine in Scotland. Clin Infect Dis. 2004;39:349–56. doi:10.1086/421947.
   PubMed Web of Science ®Google Scholar
• Hellenbrand W, Elias J, Wichmann O, Dehnert M, Frosch M, Vogel U. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect. 2013;66:48–56. doi:10.1016/j.jinf.2012.09.008.
   PubMed Web of Science ®Google Scholar
• Burgess S. Social and environmental influences affecting the risk of development of meningococcal disease: considerations for prehospital care. J Emerg Prim Health Care. 2006;4:1–10.
   Google Scholar
• Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89:1064–68. doi:10.1136/adc.2003.036004.
   PubMed Web of Science ®Google Scholar
• Stuart JM, Middleton N, Gunnell DJ. Socioeconomic inequality and meningococcal disease. Commun Dis Public Health. 2002;5:327–28.
   PubMedGoogle Scholar
• Lecocq H, Parent Du Châtelet I, Taha MK, Lévy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34:2240–50. doi:10.1016/j.vaccine.2016.03.020.
   PubMed Web of Science ®Google Scholar
• Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123:e502–9. doi:10.1542/peds.2008-0581.
   PubMed Web of Science ®Google Scholar
• Garralda ME, Gledhill J, Nadel S, Neasham D, O’Connor M, Shears D. Longer-term psychiatric adjustment of children and parents after meningococcal disease. Pediatr Crit Care Med. 2009;10:675–80. doi:10.1097/PCC.0b013e3181ae785a.
   PubMed Web of Science ®Google Scholar
• Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, Schneerson, R, Robbins, JB, Miller, MA,. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis. 2011;53:e117–24. doi:10.1093/cid/cir500.
   PubMed Web of Science ®Google Scholar
• van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, Leib, SL, Mourvillier, B, Ostergaard, C, Pagliano, P, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37–62. doi:10.1016/j.cmi.2016.01.007.
   PubMed Web of Science ®Google Scholar
• Roed C, Omland LH, Skinhoj P, Rothman KJ, Sorensen HT, Obel N. Educational achievement and economic self-sufficiency in adults after childhood bacterial meningitis. JAMA. 2013;309:1714–21. doi:10.1001/jama.2013.3792.
   PubMed Web of Science ®Google Scholar